Clinical Trial: A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma

Brief Summary: To treat patients with scleroderma by blocking the expression of LOXL2. The investigators first need to confirm (through observation) that LOXL2 is overexpressed in disease.

Detailed Summary: Scleroderma is a chronic skin-hardening disease. There are two types of scleroderma. The first type is called limited cutaneous scleroderma, where disrupted blood flow causes skin discoloration and sometimes patients experience high blood pressure in their arteries. The second type is called diffuse cutaneous scleroderma and it is much more aggressive, affecting a larger area of skin causing organ damage. This study will determine if the disease is associated with an elevated expression of LOXL2 levels in tissue samples from patients.
Sponsor: Gilead Sciences

Current Primary Outcome: Summarized the number and percentage of subjects with elevated LOXL2 levels [ Time Frame: Baseline ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Gilead Sciences

Dates:
Date Received: June 5, 2013
Date Started: April 2013
Date Completion:
Last Updated: April 16, 2014
Last Verified: April 2014